Article
BeiGene Announces Acceptance and Priority Review by Health Canada of New Drug Submission for BRUKIN
Rating:
0.0
Views:
63
Likes:
1
Library:
1
Health Canada accepted BeiGene's New Drug Submission for BRUKINSA® (zanubrutinib) in Waldenström's macroglobulinemia (WM) and granted priority review.
Rate This Post
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value